KANAPH Therapeutics, Inc.

Kanaph Therapeutics operates in the biotechnology sector, with a focus on discovering drugs and conducting initial clinical trials. The company is committed to creating advanced treatments for cancer and autoimmune disorders. Their cancer treatment line features dual-specificity antibodies and compact compounds that significantly increase immune stimulation within the tumor's surroundings, leading to effective tumor removal. In addition, their autoimmune disease treatment line includes dual-specificity Fc-fusion proteins that block the alternative complement pathway, as well as angiogenesis and further complement activation.